stoxline Quote Chart Rank Option Currency Glossary
Kiora Pharmaceuticals, Inc. (KPRX)
0.53505  -0.002 (-0.36%)    12-05 15:59
Open: 0.522
High: 0.54
Volume: 35,526
Pre. Close: 0.537
Low: 0.5102
Market Cap: 4(M)
Technical analysis
2023-12-05 4:21:10 PM
Short term     
Mid term     
Targets 6-month :  0.73 1-year :  0.85
Resists First :  0.63 Second :  0.73
Pivot price 0.54
Supports First :  0.47 Second :  0.39
MAs MA(5) :  0.53 MA(20) :  0.56
MA(100) :  0.56 MA(250) :  2.06
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  44.1 D(3) :  36.9
RSI RSI(14): 44.4
52-week High :  8.51 Low :  0.46
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ KPRX ] has closed above bottom band by 41.4%. Bollinger Bands are 6.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.54 - 0.54 0.54 - 0.55
Low: 0.5 - 0.51 0.51 - 0.51
Close: 0.54 - 0.54 0.54 - 0.54
Company Description

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Headline News

Thu, 09 Nov 2023
Kiora Pharmaceuticals reports Q3 results - Seeking Alpha

Thu, 09 Nov 2023
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal ... - Yahoo Finance

Fri, 01 Sep 2023
Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 - Yahoo Finance

Wed, 23 Aug 2023
Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of ... - Yahoo Finance

Fri, 21 Jul 2023
Why Is Kiora Pharmaceuticals (KPRX) Stock Down 7% Today? - InvestorPlace

Fri, 02 Jun 2023
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 8 (M)
Shares Float 7 (M)
Held by Insiders 6.3 (%)
Held by Institutions 3.7 (%)
Shares Short 540 (K)
Shares Short P.Month 281 (K)
Stock Financials
EPS 0.77
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.04
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -38.5 %
Return on Equity (ttm) -136.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.34
Qtrly Earnings Growth 0 %
Operating Cash Flow -9 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio 0.69
PEG Ratio 0
Price to Book value 0.51
Price to Sales 0
Price to Cash Flow -0.46
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android